Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.69 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.69 |
| ▸ | APP | P05067 | 10/20 | 0.60 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.59 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.57 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.57 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.57 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.57 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.57 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.57 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.57 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374499 | 0.87 | APP (0.71) | AKR1C3AKR1C2APPAKR1C1CYP2C9 | |
| SCHEMBL3945103 | 0.86 | AKR1C3 (0.80) | AKR1C3AKR1C2APPAKR1C1CYP2C9 | |
| SCHEMBL21826168 | 0.82 | HDAC3 (0.48) | AKR1C3AKR1C2APPAKR1C1 | |
| SCHEMBL1373508 | 0.82 | AKR1C3 (1.00) | AKR1C3AKR1C2APPAKR1C1CYP2C9 | |
| SCHEMBL5790831 | 0.82 | AKR1C3 (0.49) | AKR1C3AKR1C2APPAKR1C1CYP2C9 | |
| SCHEMBL411735 | 0.81 | APP (0.76) | AKR1C3AKR1C2APPAKR1C1CYP2C9 | |
| SCHEMBL19469650 | 0.77 | AKR1C1 (0.50) | AKR1C3AKR1C2AKR1C1DHODH | |
| SCHEMBL21874201 | 0.76 | APP (0.69) | AKR1C3AKR1C2APPAKR1C1CYP2C9 | |
| SCHEMBL1371930 | 0.76 | APP (0.82) | AKR1C3AKR1C2APPAKR1C1CYP2C9 | |
| SCHEMBL1373506 | 0.75 | APP (1.00) | AKR1C3AKR1C2APPAKR1C1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065567-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND MULTIPLE SCLEROSIS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-05 | — | — | US | claimed |
| US-20130165505-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-27 | — | — | US | claimed |
| US-7662995-B2 | 1-(2-Fluoro-4'-trifluoromethylbiphenyl-4-yl)cyclopropanecarboxylic acid, for example; treatment and/or prevention of Alzheimer's disease; inhibiting the release of A beta 42 peptide thereby being able to modulate gamma-secretase activity without affecting other important metabolic processes | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-02-16 | — | — | US | claimed |
| EP-2046119-A2 | TREATMENT OF PSYCHIATRIC DISORDERS | Myriad Genetics, Inc. (US) | 2009-04-15 | — | — | EP | claimed |
| WO-2008036733-A2 | METHODS FOR TREATMENT OF VESICLE TRANSPORT DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| US-20080033045-A1 | TREATMENT OF PSYCHIATRIC DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2008-02-07 | — | — | US | claimed |
| WO-2008006099-A2 | TREATMENT OF PSYCHIATRIC DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-01-10 | — | — | WO | claimed |
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070232672-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-05 | — | — | US | claimed |
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MYRIAD GENETICS, INCORPORATED (US) | 2007-01-18 | — | — | US | claimed |
| WO-2006020850-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| WO-2006020852-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| WO-2006020853-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-9592210-B2 | 1-phenylalkanecarboxylic acid derivatives for the treatment of cognitive impairment | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-03-14 | — | — | US | disclosed |
| WO-2015173133-A1 | FORMULATIONS AND METHODS OF TREATING ALZHEIMER'S DISEASE AND OTHER PROTEINOPATHIES BY COMBINATION THERAPY | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-11-19 | — | — | WO | disclosed |
| WO-2006020850-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006001877-A2 | COMBINATION TREATMENT FOR NEURODEGENERATIVE DISORDERS COMPRISING R-FLURBIPROFEN | MYRIAD GENETICS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288375-A1 | Method and composition for treating neurodegenerative disorders | MYRIAD GENETICS, INCORPORATED (US) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MME, AVPR1B, AVPR2 | AKR1C3 813/4885AKR1C2 517/4885APP 2522/4885 |
| US-20070232672-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | AKR1C3 454/4885AKR1C2 787/4885APP 21/4885 |
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | AKR1C3 484/4885AKR1C2 861/4885APP 29/4885 |
| US-20130165505-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | PSEN1, PSEN2, NAT1 | AKR1C3 505/4885AKR1C2 615/4885APP 15/4885 |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | PSEN2, APP, PSEN1 | AKR1C3 1915/4885AKR1C2 2052/4885APP 2/4885 |
| US-20150065567-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND MULTIPLE SCLEROSIS | PSEN1, APP, PSEN2 | AKR1C3 740/4885AKR1C2 846/4885APP 2/4885 |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | AKR1C3 454/4885AKR1C2 787/4885APP 21/4885 |
| US-20080033045-A1 | TREATMENT OF PSYCHIATRIC DISORDERS | SLC6A3, SLC6A2, FKBP5 | AKR1C3 2969/4885AKR1C2 2443/4885APP 2500/4885 |
| US-20050288375-A1 | Method and composition for treating neurodegenerative disorders | GRIN2A, GRIN2B, GRIN3A | AKR1C3 160/4885AKR1C2 446/4885APP 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.